Autonomix Medical to Unveil Long-Term Pancreatic Cancer Pain Ablation Data at SSO Phoenix
Autonomix Medical will present long-term clinical data on its transvascular RF energy-based ablation for pancreatic adenocarcinoma pain at the Society of Surgical Oncology annual meeting in Phoenix, March 5–7, 2026. The oral podium session will highlight denervation efficacy and potential improvements in chronic pain control for pancreatic cancer patients.
1. Presentation Overview
Autonomix’s Clinical Development Engineer Clarke Wilkirson, PhD, will deliver a five-minute oral podium presentation (Submission ID 2249416) titled "Pain Mitigation in Pancreatic Adenocarcinoma: A Long-Term Analysis of Denervation via Transvascular RF Energy-Based Ablation" at the 2026 Society of Surgical Oncology annual meeting in Phoenix, March 5–7, followed by a two-minute Q&A.
2. Clinical Data Focus
The long-term analysis evaluates the effectiveness of minimally invasive transvascular RF energy–based denervation in reducing chronic pain among pancreatic cancer patients, aiming to demonstrate sustained pain relief and improved quality of life metrics over an extended follow-up period.
3. Technology Platform and Future Outlook
Autonomix’s catheter-based microchip sensing array is designed to detect and differentiate neural signals for targeted ablation, creating a platform for transvascular diagnosis and treatment across indications such as cardiology, hypertension and chronic pain, with current trials focused on pancreatic cancer pain management.